cidara therapeutics inc - CDTX
CDTX
Close Chg Chg %
221.32 0.06 0.03%
Open Market
221.38
+0.06 (0.03%)
Volume: 2.69M
Last Updated:
Jan 6, 2026, 4:00 PM EDT
Company Overview: cidara therapeutics inc - CDTX
CDTX Key Data
| Open $221.32 | Day Range 221.28 - 221.41 |
| 52 Week Range 15.22 - 221.41 | Market Cap N/A |
| Shares Outstanding NaN | Public Float N/A |
| Beta 1.53 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$11.78 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 976.02K |
CDTX Performance
| 1 Week | 0.00% | ||
| 1 Month | 0.26% | ||
| 3 Months | 118.07% | ||
| 1 Year | 920.18% | ||
| 5 Years | 371.02% |
CDTX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
An error occurred while fetching the data.
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Cidara Therapeutics Inc - CDTX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 49.57M | 64.29M | 63.91M | 1.27M | |
Sales Growth
| +310.81% | +29.69% | -0.60% | -98.00% | |
Cost of Goods Sold (COGS) incl D&A
| 189.00K | 143.00K | 1.52M | 233.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 189.00K | 143.00K | 118.00K | 233.00K | |
Depreciation
| 189.00K | 143.00K | 118.00K | 233.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | -24.34% | +965.03% | -84.70% | |
Gross Income
| 49.38M | 64.14M | 62.38M | 1.04M | |
Gross Income Growth
| - | +29.89% | -2.75% | -98.33% | |
Gross Profit Margin
| +99.62% | +99.78% | +97.62% | +81.73% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 91.64M | 93.86M | 86.86M | 92.26M | |
Research & Development
| 73.09M | 75.52M | 68.53M | 71.88M | |
Other SG&A
| 18.55M | 18.34M | 18.33M | 20.38M | |
SGA Growth
| +9.58% | +2.43% | -7.46% | +6.21% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 84.88M | - |
EBIT after Unusual Expense
| (42.26M) | (29.72M) | (24.48M) | (176.10M) | |
Non Operating Income/Expense
| - | 191.00K | 2.00M | 5.81M | |
Non-Operating Interest Income
| - | 191.00K | 2.00M | 5.81M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 212.00K | - |
Interest Expense Growth
| - | - | - | -19.08% | - |
Gross Interest Expense
| - | - | - | 212.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (42.47M) | (29.53M) | (22.49M) | (170.29M) | |
Pretax Income Growth
| +41.11% | +30.47% | +23.84% | -657.25% | |
Pretax Margin
| -85.67% | -45.93% | -35.19% | -13,356.16% | |
Income Tax
| - | - | 272.00K | 443.00K | - |
Income Tax - Current - Domestic
| - | - | 272.00K | 443.00K | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (42.47M) | (29.80M) | (22.93M) | (170.29M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (42.47M) | (29.80M) | (22.93M) | (170.29M) | |
Net Income Growth
| +43.28% | +29.83% | +23.05% | -642.62% | |
Net Margin Growth
| -85.67% | -46.35% | -35.88% | -13,356.16% | |
Extraordinaries & Discontinued Operations
| - | - | - | 2.26M | - |
Discontinued Operations
| - | - | - | 2.26M | - |
Net Income After Extraordinaries
| (42.47M) | (29.80M) | (22.93M) | (168.03M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (42.47M) | (29.80M) | (22.93M) | (168.03M) | |
EPS (Basic)
| -16.1922 | -8.5314 | -5.2458 | -26.4626 | |
EPS (Basic) Growth
| +55.06% | +47.31% | +38.51% | -404.45% | |
Basic Shares Outstanding
| 2.62M | 3.49M | 4.37M | 6.35M | |
EPS (Diluted)
| -16.1922 | -8.5314 | -5.2458 | -26.4626 | |
EPS (Diluted) Growth
| +55.06% | +47.31% | +38.51% | -404.45% | |
Diluted Shares Outstanding
| 2.62M | 3.49M | 4.37M | 6.35M | |
EBITDA
| (42.07M) | (29.57M) | (24.36M) | (90.99M) | |
EBITDA Growth
| +41.22% | +29.69% | +17.62% | -273.43% | |
EBITDA Margin
| -84.86% | -46.00% | -38.13% | -7,136.16% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 215.875 | |
| Number of Ratings | 5 | Current Quarters Estimate | -1.635 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -7.208 | |
| Last Quarter’s Earnings | -3.10 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -7.632 | Next Fiscal Year Estimate | -6.96 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | N/A | 4 | 4 |
| Mean Estimate | -1.63 | N/A | -7.21 | -6.96 |
| High Estimates | -1.24 | N/A | -5.52 | -5.62 |
| Low Estimate | -2.12 | N/A | -10.06 | -9.41 |
| Coefficient of Variance | -20.56 | N/A | -27.65 | -25.48 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 2 | 9 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 4 | 6 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Hold | Buy |
SEC Filings for Cidara Therapeutics Inc - CDTX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Cidara Therapeutics Inc - CDTX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 4, 2025 | Jeffrey L. Stein President & CEO; Director | 275,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Shane M. Ward COO & CLO | 39,674 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Shane M. Ward COO & CLO | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 14, 2025 | Leslie Tari CHIEF SCIENTIFIC OFFICER | 16,215 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $21.96 per share | 356,081.40 |
| Feb 27, 2025 | Frank L. Karbe Chief Financial Officer | 57,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Frank L. Karbe Chief Financial Officer | 115,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |